Ethnicity and Pain Reviewed

Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ALBUQUERQUE-"Ethnicity is a relatively understudied concept in pain medicine," David B. Morris, PhD, writes in his review of ethnicity and pain (Pain Clinical Updates vol. IX, no. 4, November 2001). Existing research, he said, has provided "few firm generalizations" about the relationship between ethnicity and pain. This is due, in part, to the fact that both pain and ethnicity are "multidimensional, malleable, and shaped by culture."

ALBUQUERQUE—"Ethnicity is a relatively understudied concept in pain medicine," David B. Morris, PhD, writes in his review of ethnicity and pain (Pain Clinical Updates vol. IX, no. 4, November 2001). Existing research, he said, has provided "few firm generalizations" about the relationship between ethnicity and pain. This is due, in part, to the fact that both pain and ethnicity are "multidimensional, malleable, and shaped by culture."

Some studies suggest that minorities are less likely to receive adequate treatment for pain. Dr. Morris pointed to a US study that found no differences in the amount of opioid self-administered for acute pain among different ethnic groups, but significant differences in the amount of opioid prescribed.

Even when the prescription is adequate, he noted, "ethnic groups face inequalities that translate into poorly controlled pain." For example, pharmacies in poor, nonwhite neighborhoods may not stock adequate supplies of opioids.

Finally, Dr. Morris emphasized that although there may be measurable differences in how different ethnic groups experience pain, there are also "deep similarities." Studies of specific conditions, from cancer to childbirth, have found "major similarities among various ethnocultural groups in pain perception and response," he said.

Related Videos
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma
Experts on multiple myeloma
Expert on MM